UK ATTR Amyloidosis Launch Readiness

Tafamidis (Vyndaqel 61mg, Pfizer) is NHS England's commissioned ATTR-CM standard via NICE's standard Technology Appraisal route: originally recommended under TA696, since updated and replaced by TA984 (June 2024), with an estimated 40-50% PAS bringing its effective NHS price to roughly £12,000-18,000/year. Uptake has grown fast since 2023 commissioning (3,000-4,000 patients today, adding 1,500-2,000/year), but that growth is diagnosis-limited, not treatment-limited: true UK ATTRwt-CM prevalence is estimated at 20,000-40,000, meaning 15,000-36,000 patients remain undiagnosed. Acoramidis (Beyonttra in the UK, Bayer; marketed as Attruby in the US under the BridgeBio/Bayer partnership), MHRA-approved in late April 2025, received a positive NICE recommendation under TA1121 (published 14 January 2026), setting the second CM-stabiliser comparator bar. On the polyneuropathy side, vutrisiran (Alnylam) covers 200-300 UK ATTR-PN patients via a Managed Access Agreement rather than full NICE commissioning, leaving PN as a less mature access route than CM.

No single NICE-commissioned UK drug currently covers both cardiomyopathy and polyneuropathy, even though some ATTR patients present with mixed phenotype and today receive vutrisiran for PN with no formal CM treatment, a genuine dual-indication white space. But the harder near-term reality for any new CM stabiliser is the NICE comparator: cost-effectiveness is assessed relative to tafamidis's TA984 QALY model and now also to acoramidis's TA1121 recommendation, and a new entrant must show either superiority in QALY terms or equivalence at a lower effective NHS price against both. The National Amyloidosis Centre (NAC, UCL/Royal Free, led by Professor Hawkins) is NICE's appointed clinical expert for every ATTR appraisal to date, and its published family-cascade and pre-symptomatic ATTRv surveillance registry (400-500 patients under monitoring) is the deepest UK evidence base available to any pre-launch sponsor.

The pre-launch sequence: formal scientific collaboration with NAC (research grant, registry data access, clinical advisory relationship) is the single highest-return UK investment, typically £100,000-300,000 over 2-3 years, because NAC's clinical-expert testimony materially shapes NICE committee outcomes. In parallel, invest in the Tc-PYP nuclear-cardiology referral pathway from NHS echo labs (available at only ~50 of the relevant NHS cardiac centres) to grow the diagnosed population ahead of submission. If clinical evidence is uncertain relative to tafamidis or acoramidis, NICE's Managed Access Agreement, already precedent in ATTR via vutrisiran, offers a route to NHS access while real-world data accrues. Acoramidis's positive TA1121 recommendation (14 January 2026) has now reset the CM-stabiliser comparator bar; any new submission must be benchmarked against both tafamidis and acoramidis.

This assessment synthesises three research angles into a single UK ATTR launch readiness view: competitive positioning against tafamidis and acoramidis, diagnosis-pipeline and pre-symptomatic-cohort sizing anchored in National Amyloidosis Centre data, and anticipated NICE/NHS payer posture derived from the TA984 and TA1121 technology appraisal precedent.

Sources: NICE TA984 tafamidis decision document (updating TA696); NICE TA1121 acoramidis final guidance (14 January 2026); National Amyloidosis Centre (UCL/Royal Free) annual report and family-cascade programme data; Alnylam vutrisiran Managed Access Agreement documentation; NHS nuclear cardiology Tc-PYP capacity audit.